Classic: Sanofi Aventis Is Cutting Over 1500 Jobs Even As It Has $18.5 Billion To Spend On An Acquisition

seniors drugs

This is the new normal. There’s no money to be made in investment or hiring or anything like that, so companies are spending money on buybacks, dividends, and of course M&A (which is really just an excuse to fire workers).

The latest is drugmaker Sanofi-Aventis, which is in the middle of an $18.5 billion hostile bid for Genzyme, though they’re not even waiting for that deail to resolve itself. According to CNBC the company is cutting over 1500 workers, or at least 25% of its US pharma workforce.

NOW WATCH: Money & Markets videos

Want to read a more in-depth view on the trends influencing Australian business and the global economy? BI / Research is designed to help executives and industry leaders understand the major challenges and opportunities for industry, technology, strategy and the economy in the future. Sign up for free at

Tagged In

layoffs moneygame-us